Clinical studies show Wegovy typically produces greater weight loss, with patients losing an average of 15-20% of their body weight compared to Saxendas 5-10%
Scientists have long suspected that chronic low-grade inflammation contributes to cancer development
If you experience nausea, constipation, or other GLP-1 side effects that interfere with daily function, your clinician may recommend staying at your current dose longer or reducing the frequency temporarily
doi: 10.3389/fendo.2024.1528457 Received 14 November 2024 Accepted 30 December 2024 Published 21 January 2025 Volume 15 - 2024 Edited by Claire Joanne Stocker, Aston University, United Kingdom Reviewed by Wael Sidrak, Abou Seifein Diabetes & Endocrine Center, Egypt Frederic Illouz, CHU Angers, France Christine Trapp, Connecticut Childrens Medical Center, United States Updates Copyright 2025 Koceva, Mleku Kozamernik, Jane, Herman, Ferjan and Jensterle
But the needs of GLP-1 users could evolve significantly as new drugs come onto the market
